A Deep Dive On Early Time-to-Tocilizumab
The latest episode of the ASTCT Talks features Rahul Banerjee, MD, on bone marrow transplant and CAR-T therapy.
On the latest episode of ASTCT Talks, Rahul Banerjee, MD, advanced fellow of Bone Marrow Transplant/CAR-T Therapy in the Department of Medicine at the University of California (UC) San Francisco, and Nina Shah, MD, associate professor in the Department of Medicine at UC San Francisco, discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Shah and Banerjee, along with several colleagues, and was published in ASTCT’s Transplantation and Cellular Therapy Journal in March.
Tune in
ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.
Reference
Banerjee R, Marsal J, Huang CY, et al. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021;27(6):477.e1-477.e7. doi:10.1016/j.jtct.2021.03.004
Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT
June 2nd 2025Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.
